---
layout: post
title: "Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability"
date: 2026-02-05 18:35:53 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-05053
original_published: 2023-03-13 00:00:00 +0000
significance: 8.00
---

# Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** March 13, 2023 00:00 UTC
**Document Number:** 2023-05053

## Summary

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Abbott Diagnostics Scarborough, Inc. (Abbott) for the BinaxNOW COVID-19 Ag 2 Card, and Standard BioTools, Inc. (Standard) for the Advanta Dx SARS-CoV-2 RT-PCR Assay and Advanta Dx COVID-19 EASE Assay. FDA revoked these Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocations, which include an explanation of the reasons for each revocation, are reprinted in this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/03/13/2023-05053/revocation-of-three-authorizations-of-emergency-use-of-in-vitro-diagnostic-devices-for-detection)
- API: https://www.federalregister.gov/api/v1/documents/2023-05053

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
